Trial Profile
A Phase II, Open-Label, Single Institution Observational Study to Assess the Tolerability and Impact on Quality of Life of AZD9291 in Patients with Advanced Non Small Cell Lung Cancer (NSCLC) who have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent (ARPA)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2021
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms ARPA
- 07 Nov 2017 New trial record
- 18 Oct 2017 Results (data cut off 1 June 2017) assessing tolerability presented at the 18th World Conference on Lung Cancer